Cancer

Tonix Pharmaceuticals Announces Proposed Public Offering

CHATHAM, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmaceutical…

1 year ago

Hormone Therapy Pioneer Dr. Terri DeNeui Releases Definitive Guide to Hormone Health in New Book

EVEXIAS Health Solutions founder's first-of-its-kind book debunks the myths and misconceptions surrounding hormones in women and menSOUTHLAKE, TX / ACCESSWIRE…

1 year ago

Lazarex Cancer Foundation Founder Receives Champion for Cures Award From Leaders of 100+ Cancer Centers

Dana Dornsife, Founder and Chief Mission and Strategy Officer, Recognized by AACI for Advocating for Equity and Access Around Cancer…

1 year ago

Viome Launches Clinically Validated Oral Health and Early Stage Cancer Detection Test For Dental Professionals

Oral Health Pro with CancerDetect™ is the first-of-its-kind designed to provide essential oral health insights with the goal of hyper-personalized…

1 year ago

Precipio Continues to Sign New HemeScreen™ Customers

New customer orders received in Q3 exceed $1M annualized revenueNEW HAVEN, Conn., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Specialty cancer…

1 year ago

Nusano to Participate in October Investor Conferences

NEW YORK, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Nusano, Inc., a company reshaping the production of cancer-fighting radioisotopes, today announced…

1 year ago

Sensus Healthcare Sells Superficial Radiotherapy System to Cape Cod Hospital

Continues SRT-100+™ customer expansion to hospital oncology departments for the outpatient treatment of non-melanoma skin cancersBOCA RATON, Fla. , Sept.…

1 year ago

Biomea Fusion Announces FDA and Health Canada Clearance of the Expansion Cohorts of the Ongoing COVALENT-111 Phase II Study

The FDA and Health Canada have cleared the initiation of the expansion portion of COVALENT-111, which will evaluate BMF-219 administered…

1 year ago

IMUNON Reports Interim Progression-Free Survival and Overall Survival Data in Phase 1/2 OVATION 2 Study in Advanced Ovarian Cancer

Intent-to-treat population shows 9-month OS improvement over control arm Subgroup of patients treated with IMNN-001 + PARPi shows meaningful PFS…

1 year ago

Theriva Biologics to Participate in the Emerging Growth Conference

ROCKVILLE, Md., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed…

1 year ago